The National Institute of Allergy and Infectious Diseases (NIAID) has issued a Request for Information (RFI) seeking input from product developers on vaccine formulation technologies to develop dry vaccines against NIAID Category A, B and C priority pathogens.
The primary focus of the RFI is to gather information for Biodefense vaccine development about available solid vaccine formulations that increase duration of stability, eliminate cold chain requirements and minimize the need for preservatives.
Of greatest interest are dry vaccine formulations that rapidly achieve protective efficacy in a single vaccination, although information on dry vaccine formulations that require multiple administrations to be effective may also be submitted. Dry vaccine formulations may contain adjuvants to achieve a rapid immune response.
Technologies may include but are not limited to lyophilization, spray drying, foam drying, nanoparticles and other emerging drying technologies.
Further details are available under Solicitation Number: RFI-NOT-AI-12-058. The response deadline is November 30, 2012.
